LENZ Therapeutics Stock (NASDAQ:LENZ)

Ownership Financials Chart Transcripts

Previous Close

$23.89

52W Range

$14.42 - $38.93

50D Avg

$23.81

200D Avg

$25.56

Market Cap

$635.14M

Avg Vol (3M)

$208.97K

Beta

0.42

Div Yield

$7.21

LENZ Company Profile

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 22, 2024

Website

LENZ Performance

LENZ Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$15.00M	-
Operating Income	$-73.11M	$-105.64M	$-60.44M
Net Income	$-124.65M	$-101.05M	$-70.76M
EBITDA	$-70.70M	$-97.29M	$-59.71M
Basic EPS	$-15.30	$-12.89	$-8.54
Diluted EPS	$-15.30	$-12.89	$-8.54

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Mar 19, 25 | 4:30 PM

Q3 24Nov 06, 24 | 8:30 AM

Q2 24Aug 16, 24 | 4:30 PM